Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RNTX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nasaruplase Gamma (LTI-01) | Pleural Effusion | Phase 2 · NCT04159831 | Completed |
| LTI-03 | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 · NCT06968845 | Recruiting |
| Caveolin-1-Scaffolding-Protein-Derived P | Idiopathic Pulmonary Fibrosis | Phase 1 · NCT04233814 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RNTX holds $43.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $6M/quarter from operations, an estimated runway of 21.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 23 · Moderate
Management believes that, based on the Company’s current operating plan, the Company’s cash, cash equivalents and investments of $ 43,627 as of June 30, 2026 will be sufficient to enable the Company to fund its planned operating expense and capital expenditure requirements into the first quarter of 2028.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNTX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →